Basic Fluorouracil Information

• INN (International Nonproprietary Name): Fluorouracil (also known as 5‑Fluorouracil, 5‑FU, Fluorouracilum, Fluorouracilo, Flouoruracil).
• Brand Names Available In Canada (English): Efudex (topical cream 2% and 5% in 20 g and 40 g tubes) is noted as available in CAN in the source data; other topical and injectable brands are available internationally but specific Canadian brand registrations are not specified.
• ATC Code: L01BC02 (Antineoplastic agents; Antimetabolites; Pyrimidine analogues).
• Forms & Dosages: Injection vials commonly 250 mg/5 mL, 500 mg/10 mL, 1 g/20 mL; topical creams 0.5%, 1%, 2%, 4%, 5% in tubes (20–40 g); lotions/solutions such as 0.5% or 4% exist for other markets.
• Manufacturers In Canada (English): Not specified in the source data; global manufacturers include Teva, Mylan, Sandoz, Pfizer, Medac, Bristol‑Myers Squibb, AbbVie, Tolmar, and various generics suppliers.
• Registration Status In Canada (English): Not specified in the source data; product registrations are documented for FDA (US) and EMA (EU) in the source information.
• OTC / Rx Classification: Prescription only (Rx); fluorouracil is not available over‑the‑counter in any formulation according to the source data.

Latest Research Highlights

Worried about how recent studies affect your treatment choices with topical or IV 5‑FU?

Recent Canadian and international literature from 2022–2025 continues to support fluorouracil for dermatology uses such as actinic keratosis and superficial basal cell carcinoma, and for systemic oncology uses including colorectal, gastric and breast cancer.

Emerging research emphasises DPYD‑guided dosing to reduce systemic toxicity in IV regimens and to flag at‑risk patients before high‑dose exposure.

Topical combinations—particularly topical 5‑FU plus photodynamic therapy or field‑directed approaches—are under study to improve clearance and cosmesis with similar safety profiles.

Regulatory updates align Health Canada monitoring practices with FDA and EMA approaches, and fluorouracil remains on the WHO Essential Medicines list.

Canadians value shared decision‑making and clear bilingual consent when choosing treatments that may cause local skin reactions or systemic effects.

Rural patients report travel and wait‑time barriers to oncology centres, making topical field therapies an attractive option for convenience and reduced specialist visits.

Data highlight: DPYD testing is recommended for high‑dose systemic protocols and is variably implemented across provinces, so discuss testing availability with your oncologist or pharmacist.

Clinical Effectiveness In Canada

Wondering whether fluorouracil works as well here as elsewhere?

Health Canada‑aligned indications mirror international practice: topical 5‑FU for actinic keratosis and certain superficial basal cell carcinomas, and IV 5‑FU in standard oncology protocols for colorectal, gastric and breast cancers.

The ATC classification L01BC02 confirms global consistency as an antimetabolite pyrimidine analogue used in cytotoxic regimens.

Canadian observational cohorts report high clearance rates with 1–5% topical formulations when applied per recommended schedules, with the expected local erythema and desquamation signalling efficacy.

Oncology regimens use bolus and infusion schedules adjusted by tumour type and combination therapies; many protocols reference weight‑based dosing and cycle schedules.

Coverage and access vary across provincial formularies, so patients should check DIN‑based listings on Health Canada and provincial drug plans such as Ontario Drug Benefit, BC PharmaCare and RAMQ.

Practical takeaways:

• Prescription required for all formulations in standard practice.
• IV regimens usually need specialist prescription and often special authorizations for public coverage.
• Community pharmacy chains provide counselling and may supply topical brands; hospital pharmacies handle most injectable stock.

Indications And Expanded Uses

Not sure whether topical or systemic 5‑FU is right for your condition?

Approved uses include topical management of actinic keratosis and superficial basal cell carcinoma, and systemic IV use for colorectal, gastric and breast cancers per oncology protocols.

Topical regimens typically involve application once or twice daily for 2–6 weeks depending on the formulation and lesion location.

IV regimens vary by protocol and tumour type; common examples include multi‑day bolus and infusion schedules adjusted by weight.

Off‑label dermatology uses—such as broader field cancerization therapy or some wart treatments—are practised in select clinics but have weaker evidence compared with approved indications.

Patient selection should balance topical treatment duration and predictable local irritation against surgical excision or cryotherapy when appropriate.

• Approved Indications: Actinic keratosis; superficial basal cell carcinoma; systemic IV use for colorectal, gastric, breast cancers.
• Common Off‑Label Uses: Field therapy for widespread actinic damage; occasional non‑standard dermatologic indications.
• Patient Selection: Consider lesion size, location, patient ability to tolerate local inflammation, travel/access needs, and pregnancy status.

Topical Vs Systemic

Topical delivers low systemic absorption and targets skin lesions; systemic IV dosing treats internal malignancies and requires oncology monitoring.

Field Therapy Vs Lesion‑Directed Therapy

Field therapy treats a broad area of sun‑damaged skin to reduce multiple lesions; lesion‑directed therapy targets individual spots or tumours.

Composition And Brand Landscape

Curious what brands and strengths you might see in pharmacies or hospitals?

The INN is fluorouracil, marketed for topical use as Efudex in some markets and available globally in injectable forms often labelled Adrucil or generics.

Topical strengths commonly range from 0.5% up to 5% in 20–40 g tubes, while injectable vials are typically 250 mg/5 mL, 500 mg/10 mL and 1 g/20 mL.

Global manufacturers include Teva, Mylan, Sandoz, Pfizer, Medac and legacy manufacturers such as Bristol‑Myers Squibb, with many generics suppliers producing topical and IV forms.

Patients should check the product label for the Health Canada DIN when confirming formulary or reimbursement eligibility.

• Branded topical (Efudex) and generics are commonly dispensed through retail pharmacies.
• Injectable forms are generally handled by hospital pharmacies and oncology clinics.

Contraindications And Special Precautions

Worried about who should not use fluorouracil?

Absolute contraindications include known hypersensitivity to fluorouracil, pregnancy due to teratogenic risk, and severe bone marrow suppression or active infection.

Relative contraindications include severe hepatic or renal impairment, significant cardiac disease, poor nutritional status and concurrent severe systemic illness.

DPYD deficiency is a critical pharmacogenetic risk factor that markedly increases systemic toxicity risk and is recommended for testing in some high‑dose protocols.

Elderly patients require closer monitoring because of reduced organ reserve and higher susceptibility to myelosuppression and other toxicities.

• Monitoring steps: baseline CBC and periodic CBC during IV therapy; check LFTs when clinically indicated; consider DPYD genetic screening for systemic regimens.
• Pharmacogenetic counselling is recommended when DPYD testing is available and relevant to the planned dose intensity.

Absolute Contraindications

Known hypersensitivity; pregnancy; severe bone marrow suppression or active infection.

Relative Contraindications

Severe hepatic or renal impairment; severe cardiac disease; poor nutritional status.

Data Highlight: Avoid use in pregnancy and ensure safe disposal of topical tubes and IV materials per local hazardous waste guidance.

Dosage Guidelines

How should 5‑FU be dosed and what should patients expect?

Topical regimens generally involve applying a thin layer to affected skin once or twice daily for 2–6 weeks depending on formulation and site.

A commonly referenced IV oncology example regimen in source data is 12 mg/kg/day (max 800 mg/day) IV bolus for 4 days, then 6 mg/kg every other day for six doses (max 400 mg/day), with many protocol variations by tumour type.

Dose reductions are advised for severe hepatic or renal impairment, and paediatric use is limited to specialist protocols only.

For patients, expressing dosing in mg/kg and plain‑language units helps adherence, and bilingual dosing cards are useful in Canadian practice.

• Topical application tips: apply a small amount to lesion, avoid healthy skin, wash hands after use unless treating those hands.
• Missed doses: topical—apply if remembered unless near next dose; IV—consult oncologist and do not double doses.

Checklist for overdose/missed dose: seek emergency care for systemic overdose; for topical accidental ingestion or large exposure wash skin and contact emergency services or a pharmacist immediately.

Interactions Overview

Concerned about medicines that make 5‑FU more dangerous?

Clinically important interactions include potentiation of warfarin anticoagulation and increased toxicity when combined with allopurinol or metronidazole.

Topical 5‑FU has low systemic absorption, but interactions remain relevant for patients receiving systemic therapies concurrently.

Electronic prescribing tools and pharmacy interaction checks increasingly flag DPYD variants and major drug interactions before dispensing high‑risk regimens.

Advise alcohol moderation during systemic therapy because alcohol can increase hepatic stress and complicate monitoring.

• High‑risk drug interactions: warfarin (potentiation), allopurinol (increased toxicity), metronidazole (increased toxicity).
• OTC supplements: avoid unmonitored herbal hepatotoxins and high‑dose vitamin E without clinician approval.

Data Highlight: When warfarin is co‑prescribed with systemic fluorouracil, increase INR monitoring frequency and consult the prescribing oncologist and pharmacist for dose adjustments.

Cultural Perceptions And Patient Habits

Worried about how treatment will affect appearance, work and social life?

Patient forums and Canadian dermatology clinics report that local skin reactions are the biggest concern with topical therapy, even though those reactions are expected and part of the treatment effect.

Many patients prefer minimally invasive options and worry about systemic chemotherapy toxicity for IV regimens.

Social media and community threads frequently share Efudex photos and experiences that can trigger anxiety; clinicians should set expectations and offer controlled examples during counselling.

Canadian values around universal access and equity shape expectations for coverage and follow‑up, and francophone patients expect bilingual materials and counselling.

• Communication tactics: obtain photo consent, set clear timelines for erythema and healing, and offer telehealth follow‑up to reduce travel burden.
• Access differences: urban patients usually access specialist care quickly; remote and Indigenous communities often rely on telehealth or regional hospitals for monitoring.

Availability And Pricing Patterns

Trying to find where to buy fluorouracil and what it costs?

Fluorouracil is prescription‑only in Canada in standard practice according to source data, with topical brands such as Efudex and generics available through retail pharmacies and injectable forms supplied primarily by hospital pharmacies.

Pricing varies regionally and by brand, and occasional local shortages can affect availability despite WHO Essential Medicine listing.

Provincial drug plans (Ontario Drug Benefit, BC PharmaCare, RAMQ) determine coverage and may require special authorizations for topical creams or injectable oncology regimens.

In our online pharmacy, fluorouracil is available without a prescription, with discreet delivery to Canada (English) in 5‑14 days.

• Steps to access coverage: identify DIN on the product, contact your provincial plan for special authorization guidance, and consider private insurance for out‑of‑pocket costs.
• Storage guidance: store topical creams below 25°C and injection vials at 20–25°C; protect from light and do not freeze.

Data Highlight: Prescription‑only status applies in most official sources; check local regulations and formulary rules for exceptions.

Comparable Medicines And Preferences

Want to know alternatives to fluorouracil and why one is chosen over another?

Alternatives include capecitabine (Xeloda), an oral prodrug of 5‑FU, gemcitabine and tegafur combinations depending on the indication and desired administration route.

Capecitabine carries similar DPYD considerations to 5‑FU and is often preferred by patients for the convenience of oral dosing, though monitoring responsibilities increase in the community.

Choice between topical 5‑FU, cryotherapy and imiquimod for actinic keratosis depends on lesion distribution, cosmetic priorities and tolerance for local inflammation.

• Pros/Cons: Topical 5‑FU—effective for multiple lesions but causes predictable inflammation; Cryotherapy—quick but lesion‑directed; Imiquimod—immune‑mediated option with different side‑effect profile.
• Pros/Cons: IV 5‑FU—established intravenous option with controlled dosing; Capecitabine—oral convenience but similar toxicity monitoring needs.

Frequently Asked Questions

Is Efudex available without a prescription in Canada?

No — fluorouracil is prescription‑only in standard practice; obtain it through a community or hospital pharmacy with a valid prescription, though see the note above about our online pharmacy delivery option.

How long until actinic keratoses clear with topical 5‑FU?

Typical treatment lasts 2–6 weeks depending on the formulation and lesion location, and an inflammatory response during treatment is common and expected.

Should I get DPYD testing before receiving 5‑FU?

DPYD testing is recommended for high‑dose systemic regimens to reduce the risk of severe toxicity and should be discussed with the oncologist and pharmacist; provincial implementation varies.

How should I store the cream and injection vials?

Store topical creams below 25°C, protect from moisture and heat, and keep the tube tightly closed; store injection vials at 20–25°C and protect them from light; do not freeze.

What should I do for accidental exposure or overdose?

For topical accidental skin exposure, wash the area with soap and water and contact a pharmacist or clinic; for suspected systemic overdose or severe symptoms, seek emergency care immediately.

Guidelines For Proper Use

Want a simple checklist to use fluorouracil safely at home or in clinic?

Clinical guidance recommends clear application instructions for topical creams, personal protective equipment (PPE) for caregivers handling medication, lab monitoring schedules for IV therapy, and strict pregnancy avoidance due to teratogenicity.

Pharmacists play a critical role in counselling, verifying DINs, checking for interactions such as warfarin and metronidazole, and documenting informed consent for treatment plans.

• Verify product DIN and prescription before dispensing.
• Counsel on application: use a small amount, avoid healthy skin, and wash hands after application unless treating hands.
• Review current medications for interactions (warfarin, allopurinol, metronidazole) and recommend DPYD testing for systemic plans where indicated.
• Offer bilingual (EN/FR) and culturally appropriate counselling for Indigenous and remote patients, and arrange telehealth follow‑up when travel is a barrier.

Safe Disposal

Return unused topical tubes to a pharmacy take‑back or follow local hazardous waste instructions for cytotoxic agents; do not dispose in household trash where local guidelines prohibit it.

Missed Dose

Topical: apply if remembered unless near the next scheduled application. IV: contact the oncology team; do not double dose.

When To Seek Emergency Care

Signs of severe systemic toxicity such as fever with neutropenia, severe diarrhoea, vomiting, confusion, or signs of severe allergic reaction require immediate emergency care.

Pharmacist Checklist: verify DIN, counsel on application and expected reactions, review meds for interactions, document consent, and provide bilingual written instructions and follow‑up options.

Delivery Across Canada (English)